
Get exclusive money-saving offers and guides
Straight to your inbox
Updated . What changed?
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
In mid November, US drugmaker Moderna announced its experimental COVID-19 vaccine was 94.5% effective in preventing the virus. The news comes just a week after Pfizer's vaccine revealed a 90% accuracy rate.
Moderna, Inc is a biotechnology business with stocks listed in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$73.94 – an increase of 1.29% over the previous week. Here's how to invest if you're based in Australia.
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was US$73.94, which is 75.34% up on its pre-crash value of US$18.23 and 312.84% up on the lowest point reached during the March crash when the shares fell as low as US$17.91.
If you had bought US$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth US$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$3,628.24.
52-week range | US$17.91 - US$178.5 |
---|---|
50-day moving average | US$132.4109 |
200-day moving average | US$86.6428 |
Target price | US$141.93 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-2.348 |
Standard brokerage - US shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $73.94 on 2020-10-16
1 week (2021-01-12) | -40.63% |
---|---|
1 month (2020-12-18) | -47.27% |
3 months (2020-10-20) | 3.69% |
6 months (2020-07-20) | -10.57% |
1 year (2020-01-17) | 258.58% |
---|---|
2 years (2019-01-18) | 343.02% |
3 years (2018-01-16) | N/A |
5 years (2016-01-16) | N/A |
Revenue TTM | US$246.7 million |
---|---|
Gross profit TTM | US$-436,100,000 |
Return on assets TTM | -12.37% |
Return on equity TTM | -29.81% |
Profit margin | -242.34% |
Book value | 6.98 |
Market capitalisation | US$49.1 billion |
TTM: trailing 12 months
There are currently 25.6 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 7.4% down from 27.6 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 39.4 million). Moderna's SIR currently stands at 0.65. In other words for every 100,000 Moderna shares traded daily on the market, roughly 650 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 60 shares are currently held short) or 0.0769% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 77 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
We're not expecting Moderna to pay a dividend over the next 12 months.
Over the last 12 months, Moderna's shares have ranged in value from as little as US$17.91 up to US$178.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.7165. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.